7748-59-6

Usage

Uses

Used in Organic Synthesis:
1,2-Dinitro-4,5-methylenedioxybenzene is used as a key intermediate in the synthesis of various organic compounds. Its unique structure allows for a range of chemical reactions, such as reduction, substitution, and rearrangement, which can lead to the formation of diverse products with potential applications in different industries.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1,2-dinitro-4,5-methylenedioxybenzene can be used as a building block for the development of new drugs. Its chemical properties make it a versatile starting material for the synthesis of various drug candidates, particularly those with potential applications in the treatment of various diseases.
Used in Chemical Research:
1,2-Dinitro-4,5-methylenedioxybenzene is also utilized in chemical research as a model compound for studying reaction mechanisms and exploring new synthetic routes. Its unique structure provides researchers with valuable insights into the reactivity and behavior of similar compounds, contributing to the advancement of chemical knowledge and the development of new synthetic strategies.
Used in Material Science:
In the field of material science, 1,2-dinitro-4,5-methylenedioxybenzene can be employed in the development of novel materials with specific properties. Its incorporation into polymers or other materials can lead to the creation of materials with enhanced characteristics, such as improved stability, reactivity, or selectivity, which can be applied in various industrial processes.

Upstream product

• 274-09-9 Methylenedioxybenzene 
• 120-57-0 piperonal 
• 94-53-1 Piperonylic acid 
• 2620-44-2 5-nitro-1,3-benzodioxole 
• 716-32-5 6-nitrobenzo[d][1,3]dioxole-5-carboxylic acid 
• 75-11-6 diiodomethane 
• 77400-30-7 1,2-dihydroxy-4,5-dinitrobenzene 
• 144-55-8 sodium hydrogencarbonate 

Downstream Products

• 105780-30-1 1,2-Dinitro-4-hydroxy-5-methoxybenzene 
• 64993-07-3 2-amino-4,5-methylenedioxy-1-nitrobenzene 
• 81864-15-5 1,2-diamino-4,5-methylenedioxybenzene dihydrochloride 

Relevant academic research and scientific papers

Quinoxaline compound, preparation method and application of quinoxaline compound in medicine

The invention provides a quinoxaline compound, a preparation method and application of the quinoxaline compound in medicine, and particularly relates to a quinoxaline compound with PAR4 antagonistic activity, a preparation method of the quinoxaline compound, a pharmaceutical composition containing the quinoxaline compound and application of the quinoxaline compound. Specifically, the invention provides a compound shown as a general formula I and/or II or a tautomer or pharmaceutically acceptable salt thereof, a preparation method of the compound, and application of the compound or the tautomer or the pharmaceutically acceptable salt in medicines for preventing and/or treating thromboembolic diseases.

Robust Photocatalytic Method Using Ethylene-Bridged Flavinium Salts for the Aerobic Oxidation of Unactivated Benzylic Substrates

7,8-Dimethoxy-3-methyl-1,10-ethylenealloxazinium chloride (1a) was found to be a superior photooxidation catalyst among substituted ethylene-bridged flavinium salts (R=7,8-diMeO, 7,8-OCH2O-, 7,8-diMe, H, 7,8-diCl, 7-CF3 and 8-CF3). Selection was carried out based on structure vs catalytic activity and properties relationship investigations. Flavinium salt 1a proved to be robust enough for practical applications in benzylic oxidations/oxygenations, which was demonstrated using a series of substrates with high oxidation potential, i. e., 1-phenylethanol, ethylbenzene, diphenylmethane and diphenylmethanol derivatives substituted with electron-withdrawing groups (Cl or CF3). The unique capabilities of 1a can be attributed to its high photostability and participation via a relatively long-lived singlet excited state, which was confirmed using spectroscopic studies, electrochemical measurements and TD-DFT calculations. This allows the maximum use of the oxidation power of 1a, which is given by its singlet excited state reduction potential of +2.4 V. 7,8-Dichloro-3-methyl-1,10-ethylenealloxazinium chloride (1 h) can be used as an alternative photocatalyst for even more difficult substrates. (Figure presented.).

HETEROCYCLIC LSF INHIBITORS AND THEIR USES

The present invention is directed to heterocyclic SV40 Factor (LSF) inhibitors and their uses. In some implementations, the present invention discloses small-molecule compounds of Formula (I). In some implementations, the compounds of Formula (I) are used

Class of large ring heterocyclic compound restraining HCV and manufacturing and uses thereof

The invention relates to a class of compounds that inhibit HCV. The compounds are represented by Formula A. The invention also relates to preparation and pharmaceutical use of the compounds.

Quinoxalin -2 (1H)-ketone compound and its preparation method and application

The invention relates to a 1-substituted-6-methoxy-7-(3-morpholine propoxy) quinoxaline-2(1H)-ketone compound which is shown as the formula (I), preparation method and an application thereof. The benzodioxole is used as the raw material and subjected to nitration reaction for two times to produce the dinitration product: 5,6-dinitrobenzo[d][1,3] dioxacyclopentane, the 5,6-dinitrobenzo[d][1,3] dioxacyclopentane is subjected to ring opening under conditions of strong alkaline to obtain the ring opening product: 2-methoxy-4,5-dinitrophenol, the 2-methoxy-4,5-dinitrophenol and 4-(3-chloropropyl) morpholine are allowed to perform nucleophilic substitution, so as to obtain 4-(3-(2- methoxy-4,5-dinitrophenoxy) propyl) morpholine, the 4-(3-(2- methoxy-4,5-dinitrophenoxy) propyl) morpholine is reduced and allowed to perform ring closing reaction with ethyl glyoxalate to produce 6-methoxy-7-(3-morpholine propoxy) quinoxaline-2(1H)-ketone, and finally the 6-methoxy-7-(3-morpholine propoxy) quinoxaline-2(1H)-ketone is allowed to react with halogenated hydrocarbon containing substituents R under the alkaline condition, so as to produce the 1-substituted-6-methoxy-7-(3-morpholine propoxy) quinoxaline-2(1H)-ketone compound. The ketone compound has inhibition effect on EGFR kinase.(img file='DDA0000468270950000011.TIF' wi='928' he='416'/).

FUSED AMINO PYRIDINE AS HSP90 INHIBITORS

The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.

Benzimidazole compound

An object of the present invention is to provide a novel chemical compound useful as a therapeutic or prophylactic agent for acid-related diseases, having an excellent inhibitory effect against gastric acid secretion, an excellent effect of maintaining the inhibitory effect against gastric acid secretion, thereby maintaining intragastric pH high for a long time, and having more safety and appropriate physicochemical stability. Provided is a compound represented by where R1 and R3 may be the same or different and each represent a hydrogen atom or a C1-C6 alkyl group; R2 represents (5,5-dimethyl-1,3-dioxan-2-yl)methoxy group, 5,7-dioxaspiro[2.5]oct-6-ylmethoxy group, 1,5,9-trioxaspiro[5.5]undec-3-ylmethoxy group, or (2,2-dimethyl-1,3-dioxan-5-yl)methoxy group; R4, R5, R6 and R7 represent a hydrogen atom, halogen atom, C1-C6 alkyl group, C1-C6 haloalkyl group, C1-C6 alkoxy group or C1-C6 haloalkoxy group; and W1 represents a single bond, methylene or ethylene group, a salt thereof or a solvate of these.

TOPOISOMERASE INHIBITORS AND PRODRUGS

Compositions and methods for treating cancer and other hyperproliferatice disease conditions with topoisomerase inhibitors and their prodrugs are disclosed.

Substituted benzazoles and methods of their use as inhibitors of Raf kinase

New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia, and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, and inducing anesthesia are disclosed by administering to an animal in need of such treatment an alkyl or azido-substituted 1,4-dihydroquinoxaline-2,3-dione or pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.